MiMedx Group, Inc. (NASDAQ:MDXG) Shares Sold by Avantax Advisory Services Inc.

Avantax Advisory Services Inc. reduced its holdings in shares of MiMedx Group, Inc. (NASDAQ:MDXG) by 21.4% in the 4th quarter, HoldingsChannel reports. The fund owned 17,916 shares of the company’s stock after selling 4,884 shares during the quarter. Avantax Advisory Services Inc.’s holdings in MiMedx Group were worth $172,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. AlphaQuest LLC purchased a new stake in MiMedx Group during the fourth quarter worth approximately $88,000. Argentarii LLC acquired a new stake in MiMedx Group during the fourth quarter worth approximately $160,000. Raymond James Financial Inc. purchased a new stake in shares of MiMedx Group during the 4th quarter worth approximately $887,000. Proficio Capital Partners LLC acquired a new position in shares of MiMedx Group in the 4th quarter valued at $443,000. Finally, M&T Bank Corp purchased a new position in shares of MiMedx Group in the 4th quarter valued at $368,000. 79.15% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at MiMedx Group

In other MiMedx Group news, CAO William Frank Iv Hulse sold 81,446 shares of the business’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $7.80, for a total value of $635,278.80. Following the transaction, the chief accounting officer now directly owns 494,774 shares of the company’s stock, valued at approximately $3,859,237.20. The trade was a 14.13 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Kimberly Maersk-Moller sold 4,106 shares of the firm’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total transaction of $32,396.34. Following the completion of the sale, the insider now owns 310,836 shares of the company’s stock, valued at $2,452,496.04. This trade represents a 1.30 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 144,018 shares of company stock valued at $1,130,312 in the last ninety days. Insiders own 1.30% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald restated an “overweight” rating and issued a $13.00 price objective on shares of MiMedx Group in a research note on Thursday, February 27th.

MiMedx Group Stock Performance

Shares of MDXG opened at $7.74 on Friday. The company’s 50 day simple moving average is $8.30 and its 200-day simple moving average is $7.89. The firm has a market cap of $1.14 billion, a PE ratio of 14.07 and a beta of 1.97. MiMedx Group, Inc. has a 12-month low of $5.47 and a 12-month high of $10.14. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings data on Wednesday, February 26th. The company reported $0.07 EPS for the quarter, meeting analysts’ consensus estimates of $0.07. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. The company had revenue of $92.91 million for the quarter, compared to analyst estimates of $89.42 million. As a group, equities analysts predict that MiMedx Group, Inc. will post 0.3 EPS for the current year.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.